Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RH5.1 and RH5.2-VLP Malaria Vaccines in Infants in Burkina Faso
NCT05790889Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Apr 2023
- Primary completion
- Oct 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of RH5.1, RH5.2-VLP in malaria, sponsored by University of Oxford. Started Apr 2023; status: completed.
02
Drugs
RH5.1RH5.2-VLP
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05790889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790889.